The patients with favourable tumour immunoprofile (high tumour infiltrating CD8+ T-cells and iNOS+ M1 TAMs in the CT, and low tumour expression of CD47 and IDO1) might be treated with less intensive manner and remain progression-free during trastuzumab interruption while patients with non-favourable immunoprofile are candidates for experimental immunotherapeutic approaches. The gene discussed is CD8A; the disease is neoplasm.